Recent posts

APHL 2019: Strong foundations lead to new heights

By April 26, 2019

It was to be my third outing to the Association of Public Health Laboratories (APHL) Newborn Screening and Genetic Testing Symposium (NBSGTS), this being the 27th meeting of its kind, bringing some 500 members of… Read more >

Categories: Clinical
Tags: ,

Second Tier Newborn Screening Tests – Improving the Specificity of One of the Greatest Public Health Achievements

By January 29, 2019

Newborn screening for inherited disorders has been heralded as one of the 10 greatest public health achievements of the first decade of the 21st century.1 The ability to pre-symptomatically identify newborn babies at risk of… Read more >

Categories: Clinical
Tags: ,

National Newborn Screening Programs: An Overview of Challenges and Successes

By November 28, 2018

Don Mason reviews the state of newborn screening (NBS) programs around the world.

Categories: Clinical
Tags: , ,

11th ISNS European Regional Meeting, Bratislava Slovakia; An Overview

By October 30, 2018

Reflecting on a common concern in newborn screening: Reliability.

Categories: Clinical
Tags: ,

Advancing Diagnostic Screening with the RenataDX Screening System

By October 11, 2018

Waters’ legacy of purposeful innovation continues with the recently introduced RenataDX Screening System, a flow-injection tandem mass spectrometry system for high-throughput analysis of extracted dried blood spots and other physiological matrices.

Categories: Clinical
Tags: , ,

The Historical Role of Mass Spectrometry in Newborn Screening

By September 24, 2018

Newborn screening for inherited metabolic disorders dates to the early 1960s when Dr. Robert Guthrie in Buffalo, New York developed the first screening test for phenylketonuria (or PKU), a metabolic disease in which patients can’t metabolize the amino acid phenylalanine.

Categories: Clinical
Tags: , ,

Why Tandem Mass Spec is Essential for Newborn Screening

By September 7, 2018

Mass spectrometry has been game changer in newborn screening because rather than having a single test for a single condition, there was now a technique that provided a single test for a large number of different conditions.

Categories: Clinical
Tags: , ,

Reducing the Frequency of Service Engineer Visits for LC-MS Maintenance to Annual Events

By October 6, 2017

Labs like King’s Liver Laboratories in London need to analyze thousands of samples with fast turnaround times, so it’s critical to have reliable LC-MS/MS instrumentation that works every day and provides accurate and precise results.

Categories: Clinical, Customer Stories
Tags: , , ,

The Importance of Therapeutic Drug Monitoring by LC/MS Through the Lens of Organ Transplantation

By June 29, 2017

Let’s look at the area of organ transplantation as an example of how the TDM field is developing. We look at the progression from immunoassays to LC-MS assays.

Categories: Clinical
Tags:

Three Trends Fueling Therapeutic Drug Monitoring (TDM) in Asia

By June 28, 2017

Therapeutic drug monitoring (TDM) is a multi-disciplinary clinical specialty, aimed at improving patient care by monitoring drug concentration levels in blood. It enables adjustment of drug dosage for individuals to improve patient outcomes.

Categories: Clinical
Tags: